ASH Annual MeetingMeeting CoverageMultimedia Stephen J. Schuster, MD: Tisagenlecleucel Promising in Relapsed/Refractory DLBCL Friday, December 15, 2017 Dr. Schuster shares results from the global JULIET trial of the CAR T-cell therapy tisagenlecleucel in patients with relapsed/refractory diffuse large B-cell lymphoma – a patient population with the “greatest unmet need.”